Research Library / GI / Larazotide
GI researchLarazotide
AT-1001 · Larazotide acetate
An oral peptide studied principally as an adjunct in celiac disease. No consistent community amount, route and frequency is established in this entry; product- or study-specific context is listed below. Generic vial reconstitution does not fit this presentation. For research and education only, not personal medical guidance.
Quick Reference
- Evidence
- Phase III
- Presentation
- Not a generic reconstitution example
- Clinical context
- See cited product or study
- Diluent
- Not assigned
Larazotide research has focused on oral formulations, so injectable vial reconstitution is not representative.
Research schedules
Oral regimens studied with meals; protocols vary by trial
Adults with celiac diseaseClinicalTrials.gov| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Community schedules are not sufficiently consistent outside clinical research | Not established | Not established | No consistent pattern | Not established | Not established | No consistent community schedule |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Reconstitution does not fit this presentation
Larazotide research has focused on oral formulations, so injectable vial reconstitution is not representative.
Supplies & vial yield
Supply total not calculated
No standardized injectable planning basis
Larazotide research has focused on oral formulations, so injectable vial reconstitution is not representative.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- Larazotide · AT-1001 · Larazotide acetate
- Evidence / status
- Phase III. Investigational — not FDA approved
- Clinical route, frequency & duration
Celiac-disease trials: Oral regimens studied with meals; protocols vary by trial
- Community purpose
- Intestinal-barrier, tight-junction, and celiac-disease research.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
Larazotide research has focused on oral formulations, so injectable vial reconstitution is not representative.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- No compound-specific gel incidence is established in this entry.
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Intestinal tight-junction pathway modulator
An oral peptide studied principally as an adjunct in celiac disease.
Community-reported purpose
Intestinal-barrier, tight-junction, and celiac-disease research.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Celiac-disease trials
Protocol: Oral regimens studied with meals; protocols vary by trial
Population: Adults with celiac disease
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Results apply to oral, locally acting development programs and should not be extrapolated to injectable use.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is Larazotide?
An oral peptide studied principally as an adjunct in celiac disease.
Intestinal tight-junction pathway modulator
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
Larazotide research has focused on oral formulations, so injectable vial reconstitution is not representative.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeClinicalTrials.gov: Celiac-disease trials
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.